Equity Investment in PACT Pharma	12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]
Equity Investment in PACT Pharma	Note 5: Equity Investment in PACT Pharma In 2016, the Company purchased approximately 3.6 million shares of common stock of PACT Pharma, Inc. (PACT Pharma), a privately funded, early-stage biopharmaceutical company focused on adoptive cell therapy, and 1.0 million shares of Series A preferred stock. The Company determined the fair value of such investment to be insignificant to the Company’s 2016 financial statements given the start-up nature of operations of PACT Pharma, and it was recorded at a nominal amount. The Company also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma’s achievement of certain valuation thresholds pursuant to a Master Services Agreement between the Company and PACT Pharma (the PACT Agreement), which agreement has since expired. The Company determined PACT Pharma to be a variable interest entity, and that the Company has a variable interest in PACT. However, because the Company is not the primary beneficiary of PACT Pharma, it is not required to consolidate the results of operations of PACT Pharma within its consolidated financial statements. The Company’s investment in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its consolidated statements of operations and comprehensive loss. During the year ended December 31, 2019, the Company’s share of PACT Pharma’s losses exceeded the carrying amount of the equity investment. Since the Company has no obligation to provide cash financing to PACT Pharma, no additional losses are being recorded beyond the investment’s carrying amount. For the year ended December 31, 2019, the Company recorded a $1.2 million loss for its share of PACT Pharma’s operating losses, and as of December 31, 2019 the carrying amount of the investment was zero. The unrecognized equity method losses in excess of the Company’s investment was $0.8 million as of December 31, 2019. For the year ended December 31, 2018, the Company recorded $0.9 million relating to its share of PACT Pharma’s operating losses. For the years ended December 31, 2019 and 2018, the Company determined the fair value of the warrants to be insignificant to the consolidated financial statements.

Equity Investment in PACT Pharma

12 Months Ended

Dec. 31, 2019

Note 5: Equity Investment in PACT Pharma

In 2016, the Company purchased approximately 3.6 million shares of common stock of PACT Pharma, Inc. (PACT Pharma), a privately funded, early-stage biopharmaceutical company focused on adoptive cell therapy, and 1.0 million shares of Series A preferred stock. The Company determined the fair value of such investment to be insignificant to the Company’s 2016 financial statements given the start-up nature of operations of PACT Pharma, and it was recorded at a nominal amount. The Company also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma’s achievement of certain valuation thresholds pursuant to a Master Services Agreement between the Company and PACT Pharma (the PACT Agreement), which agreement has since expired. The Company determined PACT Pharma to be a variable interest entity, and that the Company has a variable interest in PACT. However, because the Company is not the primary beneficiary of PACT Pharma, it is not required to consolidate the results of operations of PACT Pharma within its consolidated financial statements.

The Company’s investment in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its consolidated statements of operations and comprehensive loss.

During the year ended December 31, 2019, the Company’s share of PACT Pharma’s losses exceeded the carrying amount of the equity investment. Since the Company has no obligation to provide cash financing to PACT Pharma, no additional losses are being recorded beyond the investment’s carrying amount. For the year ended December 31, 2019, the Company recorded a $1.2 million loss for its share of PACT Pharma’s operating losses, and as of December 31, 2019 the carrying amount of the investment was zero. The unrecognized equity method losses in excess of the Company’s investment was $0.8 million as of December 31, 2019. For the year ended December 31, 2018, the Company recorded $0.9 million relating to its share of PACT Pharma’s operating losses.

For the years ended December 31, 2019 and 2018, the Company determined the fair value of the warrants to be insignificant to the consolidated financial statements.